The role of donor hypertension and angiotensin II in the occurrence of early pancreas allograft thrombosis

Front Immunol. 2024 May 17:15:1359381. doi: 10.3389/fimmu.2024.1359381. eCollection 2024.

Abstract

Background: About 10-20% of pancreas allografts are still lost in the early postoperative period despite the identification of numerous detrimental risk factors that correlate with graft thrombosis.

Methods: We conducted a multicenter study including 899 pancreas transplant recipients between 2000 and 2018. Early pancreas failure due to complete thrombosis, long-term pancreas, kidney and patient survivals were analyzed and adjusted to donor, recipient and perioperative variables using a multivariate cause-specific Cox model stratified to transplant centers.

Results: Pancreas from donors with history of hypertension (6.7%), as well as with high body mass index (BMI), were independently associated with an increased risk of pancreas failure within the first 30 post-operative days (respectively, HR= 2.57, 95% CI from 1.35 to 4.89 and HR= 1.11, 95% CI from 1.04 to 1.19). Interaction term between hypertension and BMI was negative. Donor hypertension also impacted long-term pancreas survival (HR= 1.88, 95% CI from 1.13 to 3.12). However, when pancreas survival was calculated after the postoperative day 30, donor hypertension was no longer a significant risk factor (HR= 1.22, 95% CI from 0.47 to 3.15). A lower pancreas survival was observed in patients receiving a pancreas from a hypertensive donor without RAAS (Renin Angiotensin Aldosterone System) blockers compared to others (50% vs 14%, p < 0.001). Pancreas survival was similar among non-hypertensive donors and hypertensive ones under RAAS blockers.

Conclusion: Donor hypertension was a significant and independent risk factor of pancreas failure. The well-known pathogenic role of renin-angiotensin-aldosterone system seems to be involved in the genesis of this immediate graft failure.

Keywords: allograft thrombosis; body mass index (BMI); high blood pressure; immunothrombosis; pancreas transplantation; pre-procurement pancreas suitability score.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Allografts
  • Angiotensin II*
  • Female
  • Graft Rejection / immunology
  • Graft Survival
  • Humans
  • Hypertension* / etiology
  • Male
  • Middle Aged
  • Pancreas Transplantation* / adverse effects
  • Retrospective Studies
  • Risk Factors
  • Thrombosis* / etiology
  • Tissue Donors*

Substances

  • Angiotensin II

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by grants from the French society of Diabetes (SFD), the French national agency for biomedicine (ABM), and the Foundation for Medical Research (FRM; #FDM202106013424).